This page uses content from Wikipedia and is licensed under CC BY-SA.

3,4-Methylenedioxyphentermine

3,4-Methylenedioxyphentermine
Methylenedioxyphentermine.svg
Names
IUPAC name
1-(1,3-Benzodioxol-5-yl)-2-methylpropan-2-amine
Other names
3,4-Methylenedioxyphentermine;
3,4-Methylenedioxy-alpha,alpha-dimethyl-1-ethane
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
Properties
C11H15NO2
Molar mass 193.246 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

3,4-Methylenedioxyphentermine (MDPH) is a lesser-known psychedelic drug. MDPH was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the dosage range is listed as 160–240 mg, and the duration as 3–5 hours.[1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ MDPH entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.